

IV lidocaine has no meaningful impact in fibromyalgia

June 20 2016



(HealthDay)—For patients with fibromyalgia, use of intravenous



lidocaine has no meaningful impact, according to a study published online June 16 in the *International Journal of Rheumatic Diseases*.

Ana Laura Albertoni Giraldes, M.D., from the Federal University of São Paulo in Brazil, and colleagues conducted a randomized trial involving patients with fibromyalgia. Participants were randomized to receive lidocaine in saline solution or saline solution once a week for four weeks. All patients received amitriptyline for eight weeks. Patients underwent pain assessment, completed the fibromyalgia impact questionnaire, and had levels of interleukins (IL) 1, 6, and 8 measured before and after treatment.

The researchers found that the lidocaine group had lower pain intensity at week two of treatment, but not at other time points assessed during eight weeks. Both groups experienced a reduction in pain intensity at eight weeks after the start of treatment. There was no difference between the groups in use of acetaminophen and tramadol, or in plasma levels of IL-1, -6, and -8. There was no difference between the groups in clinical manifestations or side effects.

"The combination of 240 mg of intravenous lidocaine (once a week for four weeks) with 25 mg of amitriptyline for eight weeks had no meaningful <u>impact</u> in fibromyalgia patients," the authors write.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: IV lidocaine has no meaningful impact in fibromyalgia (2016, June 20) retrieved 4 July 2023 from https://medicalxpress.com/news/2016-06-iv-lidocaine-meaningful-impact-fibromyalgia.html



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.